<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ATSI</title>
	<atom:link href="http://www.stockbloghub.com/tag/atsi/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ATSI) ATS Medical Receives Canadian Approval</title>
		<link>http://www.stockbloghub.com/2010/03/25/atsi-ats-medical-receives-canadian-approval/31649</link>
		<comments>http://www.stockbloghub.com/2010/03/25/atsi-ats-medical-receives-canadian-approval/31649#comments</comments>
		<pubDate>Fri, 26 Mar 2010 00:57:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31649</guid>
		<description><![CDATA[ATS Medical, Inc. (ATSI) recently received the Health Canada-Medical Device Bureau, Therapeutic Products Programme’s approval for commercialization of the ATS Simulus Annuloplasty Product Line for valve repair in Canada. The approval expands ATS Medical’s presence in Canada. The company has selected Canadian Hospital Specialties Limited as its distribution partner. Canadian Hospital Specialties Limited is a significant player in the healthcare market throughout Canada. ATS Medical’s Simulus product portfolio includes flexible, semi-rigid and adjustable annuloplasty rings and bands. These products are used in mitral and tricuspid valve repair. It has been recognized that valve repair is the standard therapy for diseased or damaged mitral valves compared to valve replacement. ATS Medical’s Simulus products are well accepted by cardiac surgeons as a result of their enhanced features. Simulus annuloplasty products provide physiologic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/atsi-ats-medical-receives-canadian-approval/31649/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATSI) ATS Medical Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/03/12/atsi-ats-medical-incorporated-bear-of-the-day/30493</link>
		<comments>http://www.stockbloghub.com/2010/03/12/atsi-ats-medical-incorporated-bear-of-the-day/30493#comments</comments>
		<pubDate>Fri, 12 Mar 2010 18:45:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30493</guid>
		<description><![CDATA[ATS Medical, Inc. (ATSI) is one of the leading players in the mechanical heart valve market in the world. While mechanical heart valves are still growing in international markets, demand for this product is declining in the U.S. markets where tissue valves are more in favor. We believe overseas markets will eventually adopt this trend, as well. Therefore, the company has started increasing its presence in the tissue valve market, and expanding its offering of complementary products has fueled ATS Medical&#8217;s growth. In the fourth quarter, ATS Medical reported a loss of $0.05 per share, worse than the Zacks Consensus Estimate of loss per share of $0.01. Based on the company&#8217;s performance, we downgrade the stock to Underperform with a target price of $2.30, based on a price-to-sales ratio of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/12/atsi-ats-medical-incorporated-bear-of-the-day/30493/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATSI) ATS Medical Analysts Downgrade The Stock</title>
		<link>http://www.stockbloghub.com/2010/03/10/atsi-ats-medical-analysts-downgrade-the-stock/30294</link>
		<comments>http://www.stockbloghub.com/2010/03/10/atsi-ats-medical-analysts-downgrade-the-stock/30294#comments</comments>
		<pubDate>Thu, 11 Mar 2010 02:34:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30294</guid>
		<description><![CDATA[We recently downgraded ATS Medical, Inc. (ATSI) to ‘Underperform’ with a target price of $2.30 based on a P/S of 2.0x our fiscal 2010 revenue estimate of $82 million. ATS Medical recently reported fourth quarter and fiscal 2009 results. For the fourth quarter, loss per share was 5 cents, higher than the Zacks Consensus Estimate of loss of 1 cent and the year-ago loss of 2 cents. For fiscal 2009, loss per share was 9 cents, compared to the Zacks Consensus Estimate and the year-ago loss per share of 5 cents and 17 cents, respectively. Total revenues in the fourth quarter increased 3.7% year over year to $18.7 million. Excluding a favorable foreign currency translation (FX), total revenues increased 2.0% year over year. In terms of business segments, Heart valve ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/10/atsi-ats-medical-analysts-downgrade-the-stock/30294/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATSI) ATS Medical Fourth Quarter Reports Weak Results</title>
		<link>http://www.stockbloghub.com/2010/03/03/atsi-ats-medical-reports-weak-analyst-blog/29468</link>
		<comments>http://www.stockbloghub.com/2010/03/03/atsi-ats-medical-reports-weak-analyst-blog/29468#comments</comments>
		<pubDate>Wed, 03 Mar 2010 22:16:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29468</guid>
		<description><![CDATA[ATS Medical Inc. (ATSI) recently reported fourth quarter and fiscal 2009 results. For the fourth quarter, loss per share was 3 cents, higher than the Zacks Consensus Estimate of 1 cent and the year-ago figure of 2 cents. For fiscal 2009, loss per share was 7 cents, compared to the Zacks Consensus Estimate and the year-ago loss per share of 5 cents and 19 cents, respectively. Quarterly Results Total revenues in the fourth quarter increased 3.7% year over year to $18.7 million. Excluding a favorable foreign currency translation (FX), total revenues increased 2.0% year over year. In terms of business segments, Heart valve therapy revenues increased 6.3% year over year to $13.9 million. Growth was fueled by higher Tissue valve and Heart valve repair revenues, partly offset by lower Mechanical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/atsi-ats-medical-reports-weak-analyst-blog/29468/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATSI) ATS Medical Raises Expectations</title>
		<link>http://www.stockbloghub.com/2010/01/13/atsi-ats-medical-raises-expectations/24849</link>
		<comments>http://www.stockbloghub.com/2010/01/13/atsi-ats-medical-raises-expectations/24849#comments</comments>
		<pubDate>Wed, 13 Jan 2010 17:40:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24849</guid>
		<description><![CDATA[ATS Medical, Inc. (ATSI) reported preliminary results for the fourth quarter and full fiscal 2009. The company expects total revenues in the fourth quarter in the range of $18.4 million to $18.8 million, an increase of 2% to 4% over the fourth quarter of 2008. Full fiscal 2009 revenues are expected between $75.4 million and $75.8 million, an increase of roughly 15% year over year. However, expected annual revenues are lower than ATS Medical’s previous guidance of $77.0 million to $79.0 million. Lower revenue guidance can be primarily attributed to a slowdown in demand for ATS Medical’s mechanical valve business across the globe and lower-than-planned growth for the company’s surgical ablation business in the U.S. ATS Medical expects to recognize a restructuring charge related to its international organization of roughly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/atsi-ats-medical-raises-expectations/24849/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATSI) ATS Medical Gets CE Approval</title>
		<link>http://www.stockbloghub.com/2009/12/09/atsi-ats-medical-gets-ce-approval/22379</link>
		<comments>http://www.stockbloghub.com/2009/12/09/atsi-ats-medical-gets-ce-approval/22379#comments</comments>
		<pubDate>Wed, 09 Dec 2009 23:20:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22379</guid>
		<description><![CDATA[ATS Medical, Inc. (ATSI) recently received CE Mark approval to distribute the ATS 3f Enable Aortic Bioprosthesis in the European Union. The Enable valve is implanted using a sutureless technique. It is the first surgical aortic valve replacement approved for commercial use. The product will be available immediately in a soft launch in the European Union followed by full launch in the second half of 2010. The Enable valve is designed to achieve a less invasive aortic valve replacement. It has been seen that most aortic valve surgeries cannot be performed on a minimally invasive basis. This is due to the fact that precise suturing is difficult within the confined space of a minimally invasive procedure. ATS Medical’s Enable valve eliminates this handicap. Furthermore, the valve also reduces surgical procedure ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/09/atsi-ats-medical-gets-ce-approval/22379/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATSI) ATS Medical Earnings Report Meets Consensus</title>
		<link>http://www.stockbloghub.com/2009/11/04/atsi-ats-medical-earnings-report-meets-consensus/19587</link>
		<comments>http://www.stockbloghub.com/2009/11/04/atsi-ats-medical-earnings-report-meets-consensus/19587#comments</comments>
		<pubDate>Wed, 04 Nov 2009 20:48:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19587</guid>
		<description><![CDATA[ATS Medical, Inc. (ATSI) reported a third quarter 2009 net loss of 1 cent per share, in-line with the Zacks Consensus Estimate but better than the year-ago loss per share of 6 cents. Total revenues for the reported quarter were $18.8 million Incorporatedreasing 17.3% year over year. Excluding an unfavorable foreign currency translation (FX), total revenues increased 19.4% year over year. Growth was broad-based across its major business segments. Heart valve therapy revenues increased 20.5% year over year to $14.2 million. In this segment, Mechanical valve revenues increased 10% year over year to $11.6 million. This was due to higher demand for the ATS Open Pivot Mechanical Heart Valve in Asia and success from the recent launch of the AP360 valve in Japan. Tissue valve revenues were $1.4 million, compared ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/04/atsi-ats-medical-earnings-report-meets-consensus/19587/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATSI) ATS Medical Receives Approval for Cardiac Arrhythmia Treatment</title>
		<link>http://www.stockbloghub.com/2009/10/16/atsi-ats-medical-receives-approval-for-cardiac-arrhythmia-treatment/17704</link>
		<comments>http://www.stockbloghub.com/2009/10/16/atsi-ats-medical-receives-approval-for-cardiac-arrhythmia-treatment/17704#comments</comments>
		<pubDate>Fri, 16 Oct 2009 21:58:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17704</guid>
		<description><![CDATA[ATS Medical, Inc. (ATSI) yesterday received the CE Mark approval for marketing the ATS CryoMaze 10-S Surgical Cryoablation Probe used for the treatment of cardiac arrhythmias in the European Union. The new product complements the current ATS CryoMaze Probes by adding a linear cryoablation probe that provides more controlled stiffness. This enables surgeons to have more probe leverage so that they can achieve contact with the targeted tissue that is difficult to reach. The ATS CryoMaze 10-S Surgical Cryoablation Probe achieves the coldest probe temperatures needed for cardiac arrhythmia surgery. The argon-based cryoablation system can reach a temperature of -1600 Celsius versus nitrous-oxide systems that can achieve temperatures of -650 Celsius only. The colder probe temperatures provide faster and deeper lesions compared to the traditional linear lesions. The ATS CryoMaze ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/atsi-ats-medical-receives-approval-for-cardiac-arrhythmia-treatment/17704/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATSI) ATS Medical Gets FDA Approval</title>
		<link>http://www.stockbloghub.com/2009/08/28/atsi-ats-medical-gets-fda-approval/13831</link>
		<comments>http://www.stockbloghub.com/2009/08/28/atsi-ats-medical-gets-fda-approval/13831#comments</comments>
		<pubDate>Fri, 28 Aug 2009 22:49:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Ats Medical Inc]]></category>
		<category><![CDATA[ATSI]]></category>
		<category><![CDATA[Edwards Lifesciences Corp]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13831</guid>
		<description><![CDATA[ATS Medical, Inc. (ATSI) has received approval from the U.S. Food and Drug Administration (FDA) for a landmark clinical study in which cardiac surgeons will implant the company’s ATS 3f Aortic Bioprosthesis valve in a younger aortic valve replacement patient population. The clinical study will be performed to evaluate the effectiveness of ATS 3f Aortic Bioprosthesis valve in a younger population, those less than 60 years of age. The ATS 3f is a tissue valve that functions like a natural valve. It has the same tube shape that helps in maintaining a steady blood flow at a normal speed. Valves are subject to natural wear and tear. The 3f valve is used for replacing a valve in the aorta, the largest blood vessel in the body. ATS Medical is looking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/atsi-ats-medical-gets-fda-approval/13831/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

